Dr. Michael Benatar awarded $6.24 Million NIH Grant for Creation of Rare Diseases Clinical Research Consortium

NIH Funds ALS Research Consortium Headed by UM Neurologist

From left are Claes Wahlestedt, M.D., Ph.D., Jacob McCauley, Ph.D., Michael Benatar, M.D., Ph.D., Rebecca Schüle, M.D., Zane Zeier, Ph.D., Stephan Züchner, M.D., Ph.D., and Evadnie Rampersaud, Ph.D.

MIAMI, FL –The National Center for Advancing Translational Sciences and the National Institute of Neurological Disorders and Stroke have granted a $6.24 million cooperative agreement award to Dr. Michael Benatar for the establishment of a Rare Diseases Clinical Research Consortium. The consortium, to be called CReATe (Clinical Research in ALS and related disorders for Therapeutic development) will study amyotrophic lateral sclerosis (ALS) and other related rare diseases.

This unique collaborative effort will attempt to elucidate the relationship between phenotype and genotype in ALS and related disorders, search for new genetic causes of disease, identify genetic modifiers, and the development of biomarkers that may aid in therapy development.

For more details, please view the articles below.